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Abstract
A healthy, balanced diet is essential for both physical and mental well-being. Such a diet must include an adequate intake of micronutri-
ents, essential fatty acids, amino acids and antioxidants. The monoamine neurotransmitters, serotonin, dopamine and noradrenaline, are
derived from dietary amino acids and are involved in the modulation of mood, anxiety, cognition, sleep regulation and appetite. The
capacity of nutritional interventions to elevate brain monoamine concentrations and, as a consequence, with the potential for mood
enhancement, has not been extensively evaluated. The present study investigated an extract from oregano leaves, with a specified
range of active constituents, identified via an unbiased, high-throughput screening programme. The oregano extract was demonstrated
to inhibit the reuptake and degradation of the monoamine neurotransmitters in a dose-dependent manner, and microdialysis experiments
in rats revealed an elevation of extracellular serotonin levels in the brain. Furthermore, following administration of oregano extract, beha-
vioural responses were observed in mice that parallel the beneficial effects exhibited by monoamine-enhancing compounds when used in
human subjects. In conclusion, these data show that an extract prepared from leaves of oregano, a major constituent of the Mediterranean
diet, is brain-active, with moderate triple reuptake inhibitory activity, and exhibits positive behavioural effects in animal models.
We postulate that such an extract may be effective in enhancing mental well-being in humans.
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A healthy, balanced diet, including an adequate intake of
micronutrients, essential fatty acids, amino acids and
antioxidants, is essential for both physical and mental
well-being. Nutrients which are particularly important
for brain development and function include n-3 PUFA,
minerals such as Zn, Mg and Fe, and vitamins such
as folate, B vitamins and vitamins C and E(1–3). The
monoamine neurotransmitters, serotonin, dopamine and
noradrenaline (NA), are synthesised from dietary amino
acids; specifically, serotonin is synthesised from the
essential amino acid, tryptophan, and dopamine and NA
are synthesised from tyrosine. The rate of synthesis of
these neurotransmitters is therefore sensitive to the supply
of their respective precursors(4,5). Following their synthesis,
serotonin, dopamine and NA are released into the synaptic
cleft to act at post-synaptic receptor sites. Neurotransmitter
action is terminated by reuptake into the pre-synaptic
neuron through the activity of high-affinity Naþ/Cl–-depen-
dent serotonin, dopamine and NA reuptake transporters
(SERT, DAT and NAT, respectively) and enzymatic degra-
dation by monoamine oxidase (MAO; all three neurotrans-
mitters) or catechol-O-methyltransferase (dopamine and
NA)(5–7). Activity of the monoamine neurotransmitters can
thus be enhanced by inhibition of MAO and/or by inhibition
of the reuptake transporters.
Together, the activity of these three neurotransmitters
plays an essential role in many of man’s basic physiological
and behavioural functions. In particular, serotonin
(5-hydroxytryptamine (5-HT)) is implicated in cardio-
vascular regulation, respiration and thermoregulation, as
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well as in circadian rhythm entrainment, the sleep–wake
cycle, appetite, mood, aggression, sexual behaviour,
sensorimotor reactivity, pain sensitivity and learning(8);
dopamine is involved in locomotor activity, cognition,
emotion, positive reinforcement, food intake and endo-
crine regulation(9); NA is involved in mediating attention,
anxiety, arousal, food intake and learning and memory(6).
Dysregulation of the monoaminergic neurotransmitter
pathways is therefore implicated in alterations in mood,
appetite, sleep and activity, and sexual and cognitive
dysfunction(8).
Nutritional components have been demonstrated to
modulate mood and cognitive performance in healthy indi-
viduals. For example, 12 weeks’ supplementation with a
multi-vitamin/mineral composition in healthy children
resulted in improved attention, but was associated with
decrements in recognition memory(10). Several randomised,
placebo-controlled, double-blind, balanced, crossover
studies have been performed using a computerised test bat-
tery: in healthy young adults, Melissa officinalis (lemon
balm) improved attention and increased ‘calmness’, but
reduced alertness and disrupted memory performance(11);
Salvia lavandulaefolia (Spanish sage) essential oil improved
different aspects of mood(12) and memory(12,13) in healthy
young adults; Salvia officinalis improved cognitive function
in healthy older individuals and has been demonstrated to
have significant anticholinesterase inhibition effects(14).
It is likely that the mechanisms of action of vitamins/min-
erals and plant extracts, with the ability to modulate mood
and cognition, are diverse and involve several neurotrans-
mitter systems. To this end, in vitro and in vivo activity of
specific compounds or plant extracts provides important
information concerning putative mechanisms of action and
indications for mood and cognition enhancement in
human subjects. For example, constituents of liquorice
significantly inhibited radiolabelled serotonin ([3H]-5-HT)
reuptake(15), and cis- and trans-resveratrol concentration-
dependently inhibited [3H]-5-HT and radiolabelled NA
([3H]-NA) uptake, in addition to inhibiting the activity
of MAO(16). These in vitro data indicate potential antidepres-
sant-like effects through the enhancement of serotoner-
gic(15,16) or noradrenergic(16) neurotransmission. Moreover,
animal data provide evidence that natural products, such
as liquorice extract(17,18) or essential oils from Citrus
aurantium L.(19), may have antidepressant-like activity(17),
improve cognition(18) or have anxiolytic potential(19), and
the observed antidepressant-like effects of liquorice extract
may be mediated via NA and dopamine(17).
A recent empirical study comprised assessment of the
attitudes of both the general public and general prac-
titioners, with respect to the use of pharmaceuticals and
natural remedies by healthy people, to improve concen-
tration, mood and memory. The results indicated that
enhancement by means of natural remedies was more
acceptable to the general public than the use of pharma-
ceuticals for the same purpose(20). Thus, the use of
plant-derived compounds or plant extracts to improve
mood and cognition in healthy individuals is of general inter-
est, yet has not been systematically investigated to date.
In the present study, we subjected a library of several
thousand pure phytochemicals and plant extracts to a
high-throughput, non-radioactive human SERT (hSERT)
functional screening assay, whereby test compounds’
ability to inhibit the uptake of a fluorescent substrate was
measured(21). We identified a two-step, supercritical fluid
CO2 oregano extract, with a specified range of active con-
stituents, as having strong inhibitory activity. Furthermore,
the oregano extract was demonstrated to inhibit the
reuptake of radiolabelled serotonin, NA and dopamine,
as well as inhibiting MAO-A enzymatic activity. In vivo
microdialysis data further confirmed serotonergic activity
of oregano extract, and results of the forced swim
test and the marble-burying test parallel those reported
for antidepressant-like and anxiolytic-like compounds,
respectively. Finally, carvacrol (CAR), the main constituent
of oregano extract, was measurable in dose-dependent
levels in mouse plasma and brain tissue following a sub-
chronic dosing schedule.
Materials and methods
Preparation of oregano extract (ore´Vidae)
Extracts were prepared by Flavex (FLAVEX Naturextrakte
GmbH, Rehlingen, Germany). In brief, dried leaves of ore-
gano were mechanically milled and extracted with CO2
under supercritical conditions (100 bar, 458C, 1 kg CO2/kg
of plant material). The lipophilic components dissolved by
this process were transferred to a second vessel (separator),
and the final extract was obtained by reducing pressure to 60
bar at 308C. Analysis of a typical oregano extract produced
by this process, using GC/MS, revealed a total content of
essential oils of up to 89 %. The principal volatile com-
ponents, included within oregano extracts used in the
studies described below, were identified as terpinene
(0·2 %), thymol (0·2–0·4 %), 4-terpineol (0·3–1·5 %), caryo-
phyllene (1·5–1·9 %), p-cymene (2·4–7·8 %), thymoquinone
(TQ; 4–23·2 %) and CAR (50–79·9 %). The exception was
the spike assay, where an extract including 0·1 and 0·6 %
of TQ and CAR, respectively, was used (see below).
In vitro determination of mechanisms of action of oregano
extract
Cell culture. HEK-293 cells stably expressing the hSERT
were obtained from R. Blakely (Vanderbilt School of
Medicine, Nashville, TN, USA)(22). The cells were routinely
grown in poly-L-lysine-pretreated dishes in Dulbecco’s
modified Eagle’s medium (Bioconcept, Allschwil, Switzer-
land), containing 10 % dialysed fetal calf serum, penicillin,
streptomycin, L-glutamine and the antibiotic G418
Mood-enhancing potential of oregano extract 1151
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(Invitrogen, Paisley, UK), and passaged by trypsinisation
before cell confluence occurred.
Non-radioactive high-throughput screening assay. This
assay has been described in detail elsewhere(21). Briefly,
hSERT-expressing HEK-293 cells from 80 % confluent
flasks were harvested 48 h before assay and seeded
(75 000 cells/well) into poly-D-lysine-coated ninety-
six-well plates (Becton Dickinson, Bedford, MA, USA).
Immediately before assay, the medium was exchanged
for Krebs–Ringer–HEPES buffer (130mM-NaCl, 1·3mM-KCl,
2·2mM-CaCl2, 1·2mM-MgSO4, 1·2mM-KH2PO4 and 10mM-
HEPES, pH 7·3) supplemented with glucose (1·8 g/l), ascorbic
acid (100mM) and pargyline (100mM). The fluorescent
substrate 4-(4-(dimethylamino)-styryl)-N-methylpyridinium
(ASP; Sigma-Aldrich, St Louis, MO, USA) was added (final
concentration 1mM) and incubated at 378C, 5 % CO2, 95 %
humidity for 60 min. Unincorporated ASP was removed
by washing three times with 300ml Krebs–Ringer–HEPES
containing 1 mM-imipramine (IMI), and the cells were
lysed by the addition of SDS (1 % final concentration).
The incorporated ASP was quantified by fluorescence
intensity (lex ¼ 485 nm and lem ¼ 620 nm) using an Ana-
lyst System (Molecular Devices Corporation, Sunnyvale,
CA, USA). The assay was automated using the CyBio
CyBi Well for compound addition, the Labsystems Multi-
drop for ASP addition and the Titertek MAP-C system for
plate washing. The effect of oregano extract on the trans-
porter function was determined by its inclusion in the
assay at a concentration of 25mg/ml for 10 min before
and during incubation with ASP.
Radiolabelled serotonin uptake assay. On the day of
assay, hSERT-expressing HEK-293 cells from 80 % confluent
flasks were harvested by gentle washing with warm (378C)
PBS. Cells were then washed once by centrifugation,
resuspended in Krebs–Ringer bicarbonate buffer (Sigma-
Aldrich), supplemented with 100mM-pargyline, 2·2 mM-
CaCl2, 100mM-ascorbic acid and 10 mM-HEPES (pH 7·3),
and aliquoted into round-bottomed, polypropylene,
ninety-six-well microtitre plates (Nunc, Roskilde, Denmark)
at a density of 10 000 cells/well. Serotonin uptake into the
cells was determined by the addition of radiolabelled sero-
tonin ([3H]-5-HT; Amersham, Buckinghamshire, UK) at a
concentration of 20 nM, and incubation for 40 min at 378C
with gentle shaking. Subsequently, unincorporated [3H]-5-
HT was removed by filtration through Unifilter 96 GF/B
plates (Perkin Elmer, Wellesley, MA, USA) using a Tomtec
Mach III M cell harvester. The incorporated [3H]-5-HT
retained on the plates was quantified by liquid scintillation
counting using Microscint-40 and measured using a Top-
count (Perkin Elmer) with quench correction. The effects
of oregano extract on the transporter function were deter-
mined by its inclusion in the assay at a range of concen-
trations (0·03–100mg/ml) for 10 min before and during
incubation with radiolabelled serotonin.
Radiolabelled noradrenaline and dopamine uptake
assays. Measurements of NA and dopamine reuptake
inhibition by oregano extract were performed at MDS
Pharma Taiwan (Taipei, Taiwan, ROC), according to the fol-
lowing methods. MDCK cells, stably expressing the human
recombinant noradrenaline transporter (hNAT), or CHO-
Ki/hDAT cells expressing the human dopamine transporter
(hDAT) were plated 24 h before the assay. The cells
(2 £ 105/ml) were preincubated with the oregano extract
(ten concentrations; 3 ng/ml–100mg/ml) or vehicle in
modified Tris–HEPES buffer (pH 7·1) at 258C for 20 min
before the addition of 25 nM-radio-labelled NA ([3H]-NA) or
50 nM-radio-labelled dopamine ([3H]-DA), respectively, for
10 min. Cells were then rinsed twice, and solubilised
with 1 % SDS lysis buffer, and the lysate was analysed to
determine [3H]-NA or [3H]-DA uptake; specific signal
was determined in the presence of 10mM-desipramine
or -nomifensine, respectively.
Monoamine oxidase assay. In order to determine the
ability of oregano extract to act as an MAO inhibitor, the
following assay was performed(23). The organic amines
p-tyramine and benzylamine were used as substrates for
the MAO-A and MAO-B enzymes, respectively. The H2O2
produced by this reaction was quantified by reaction
with vanillic acid and catalysed by horseradish peroxidase.
The reactions were carried out in polystyrene microtitre
plates. The MAO enzymes (final concentration 2 U/ml;
Sigma-Aldrich) were mixed with either p-tyramine or ben-
zylamine (final concentration 0·5 mM; Sigma-Aldrich), as
appropriate, and the chromogenic solution (vanillic acid
(Sigma-Aldrich), 4-aminoantipyrine (Sigma-Aldrich) and
horseradish peroxidase (Sigma-Aldrich); final concen-
trations of 0·25, 0·125 mM and 1 U/ml, respectively) in
0·2 M-potassium phosphate buffer (pH 7·6). Following
40 min of incubation at 378C, absorbance was measured
at 495 nm on a microtitre plate absorbance reader (Spectra-
max M5; Molecular Devices Corporation). The assay was
performed in duplicate, and reference inhibitors such as
clorgyline (for MAO-A) and pargyline (for MAO-B) were
used as controls. In order to determine the maximum con-
centration of oregano extract, which could be tested in
this assay, the effect of oregano extract on the horseradish
peroxidase-catalysed portion of the reaction was indepen-
dently determined by replacing the MAO enzyme with
H2O2 (final concentration 0·2 mM; Molecular Probes,
Eugene, OR, USA). Thus, oregano extract was tested in
the MAO assay up to the maximum concentration, which
showed no interference in the horseradish peroxidase
reaction or, in the case of no interference, a maximum
concentration of 100mg/ml.
Determination of reversibility of monoamine oxidase
inhibition. Dialysis was used to determine whether ore-
gano extract acts as a reversible inhibitor or a deactivator
of MAO(24). Reversibility of MAO inhibition is important
for the prevention of serious side effects associated with
the first-generation, non-selective, irreversible MAO inhibi-
tor antidepressants, caused by interactions with dietary
tyramine(25). MAO (4 U/ml) in the absence or the presence
A. O. Mechan et al.1152
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of oregano extract was preincubated in 0·1 M-potassium
phosphate buffer (pH 7·4) at 378C for 15 min. Sub-
sequently, 0·5 ml of the mixture was dialysed at 48C, with
shaking, v. 40 ml of outer buffer (0·1 M-potassium phos-
phate, pH 7·4, 5 % sucrose). Spectra/Por dialysis tubing
with a 6000–8000 molecular weight cut-off (Serva, Heidel-
berg, Germany) was used, and the outer buffer was
replaced with fresh buffer after approximately 3, 18 and
21 h. Non-dialysed aliquots of each mixture were main-
tained at 48C over the same time period. In order to
evaluate reversibility of the inhibition, MAO activity was
measured as described above 24 h after the start of dialysis.
The enzymatic activity in the dialysed mixture was
compared with the corresponding non-dialysed aliquot
and expressed as a percentage of control.
Oregano extract and carvacrol/thymoquinone spike
assay. In order to determine whether two of the main com-
ponents of oregano extract, TQ and CAR, were responsible
for the hSERT inhibitory effects of the extract, the following
assay was performed. An oregano extract containing very
low levels of TQ (0·1 %; 0·244mM) and CAR (0·6 %; 1·6mM)
was chosen for the assay. Exogenous TQ or CAR (at a
range of concentrations from 1 to 100mM; Sigma-Aldrich)
was added to the half maximal inhibitory concentration
(IC50) of oregano extract (40mg/ml), and radiolabelled ser-
otonin uptake assays were performed as described above.
In vivo efficacy of oregano extracts
Animals and husbandry. At Porsolt & Partners Pharma-
cology (Le Genest-St-Isle, France), male Rj:NMRI mice
(5–6 weeks of age; Elevage Janvier, Le Genest-St-Isle,
France) were used for acute testing of oregano extract.
Mice were housed in groups of ten and, at the start of
the experimental phase, were randomly assigned to test
groups (n 15). Each individual mouse was only tested in
one of the three behavioural paradigms.
In-house, male Balb/c mice (5–6 weeks of age; RCC,
Fu¨llinsdorf, Switzerland) were used for sub-chronic testing
of oregano extract. Mice were housed in groups of three
and were randomly assigned to test groups (n 10) at the
start of the experimental phase. These mice were selected
based on the evidence that they demonstrate higher base-
line immobility and lower overall variability than several
outbred strains(26) and enabled verification of the beha-
vioural effects of oregano extract in a second mouse strain.
For the in vivo microdialysis study (Leicester School of
Pharmacy, De Montfort University, Leicester, UK), male
Sprague–Dawley rats (250–320 g; Harlan UK Limited, Bice-
ster, UK) were housed in groups of four to five.
In all cases, animals were housed under conditions of
controlled temperature and humidity and a 12 h light–
12 h dark cycle, with free access to food and water. Mice
and rats were acclimatised to the respective testing facility
for a minimum of 5 d before commencement of testing.
All animal studies were performed under appropriate
personal and institutional licenses and in accordance with
the relevant national and international animal protection
legislation.
Test compounds and compound administration. For
intraperitoneal (i.p.) administration, oregano extract
(FLAVEX) was prepared in a suspension with 3% dimethyl-
sulphoxide (DMSO; Coope´ration Pharmaceutique Franc¸aise,
Melun Ce´dex, France) and 3% Tween 80 (Sigma-Aldrich) in
physiological saline (0·9% NaCl; Laboratoire Aguettant,
Lyon, France); for per os (p.o.) administration, oregano
extract was diluted in tocopherol-stripped corn oil (Dyets,
Inc., Bethlehem, PA, USA). In behavioural studies, the
reference compounds, fluoxetine (FLU; Merck, Darmstadt,
Germany or Sigma-Aldrich), clobazam (CLO; Sanofi-
Synthe´labo, Paris, France) and venlafaxine (VEN; Merck),
were dispersed in 0·2% hydroxypropylmethylcellulose
(Sigma-Aldrich); the reference compound imipramine
hydrochloride (IMI; Sigma-Aldrich) was dissolved in saline;
vehicle-treated (VEH) control mice were administered
either 3% DMSO/3% Tween 80 in saline (i.p.) or corn oil
(p.o.). In the rat microdialysis studies, oregano extract
was prepared in 3% DMSO/3% Tween 80 in saline, and
the reference compounds, FLU and IMI, were dissolved
in saline.
In all acute behavioural studies, test compounds and
vehicle were administered i.p., in a volume of 10 ml/kg,
30 min before commencement of the behavioural tests. In
studies where sub-chronic treatment was employed, mice
were administered test compounds or vehicle (10 ml/kg,
p.o.) 24, 5 and 1 h before the start of the test, unless other-
wise stated. In the rat microdialysis study, test compounds
or vehicle were administered i.p., in a volume of 1 ml/kg,
at 0, 60 and 120 min. Doses of oregano extract and refer-
ence compounds employed for the different behavioural
and microdialysis studies are detailed below.
Behavioural tests
Forced swim test. The forced swim (behavioural des-
pair) test was developed to determine the potential anti-
depressant activity of pharmaceutical compounds,
whereby effective compounds reduce the immobility beha-
viour of mice forced to swim in a narrow cylinder(27). At
Porsolt & Partners Pharmacology, the test was performed
in the following manner: mice were individually placed
in a clear perspex cylinder containing water (228C), from
which they could not escape, and were observed for swim-
ming and immobility behaviour, which was measured
using a stopwatch and recorded in a score sheet. The test
lasted for 6 min, and the duration of immobility during
the last 4 min of the test was subsequently analysed(27).
Oregano extract was tested at doses of 10, 30 and
60 mg/kg, i.p.; IMI (32 mg/kg, i.p.; tricyclic antidepressant
with strong serotonin and NA reuptake inhibition activity)
and VEN (16 mg/kg, i.p.; serotonin/NA reuptake inhibitor)
were used as the reference compounds.
Mood-enhancing potential of oregano extract 1153
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In-house, the forced swim test was performed using
an automated recording system as follows. Mice were indi-
vidually placed in a polypropylene cylinder containing
water (22 ^ 18C), from which they could not escape.
Experiments were monitored via a black and white CCD
camera mounted above the swim test arena, and duration
of immobility and swimming behaviour was automatically
recorded via VideoMot2 software (TSE Systems GmbH,
Bad Homburg, Germany). The test lasted for 6 min, and
the duration of immobility during the last 4 min of the
test was subsequently analysed. Oregano extract was
tested at doses of 75, 150 and 300 mg/kg, p.o.; IMI
(32 mg/kg, p.o.) was used as the reference compound.
Marble-burying test. The marble-burying test, devel-
oped to measure anxiolytic(28,29) or obsessive–compul-
sive(30) behaviour, was performed as described by
Broekkamp et al.(31). Briefly, mice were individually tested
in a transparent plastic cage (33 £ 21 £ 18 cm), containing
5 cm sawdust spread evenly across its base. A total of
twenty-five marbles (1 cm in diameter) were grouped in
the centre of the cage, and the number of marbles, which
were (at least two-thirds) covered with sawdust, was
counted at the end of a 30 min test period. Oregano extract
was tested at doses of 10, 30 and 60 mg/kg, i.p.; FLU
(32 mg/kg, i.p.; selective serotonin reuptake inhibitor) and
VEN (16 mg/kg, i.p.) were used as the reference com-
pounds. In order to ensure that marbles were not buried
purely due to possessing an unfamiliar odour, each test
cage and set of marbles were subjected to a 15 min period
during which ten naive mice were left to explore the
cage, thus ‘impregnating’ the test arena with a typical
mouse odour.
Light–dark box test. The light–dark box test, which is
used to detect the potential anxiolytic activity of com-
pounds, was performed as described by Crawley(32). Briefly,
the light–dark box comprised a light, open compartment
(25 cm (height) £ 27 cm (width) £ 27 cm (length)) and
a dark, closed compartment (20 cm (height) £ 27 cm
(width) £ 27 cm (length)). At the start of a 3 min test, each
mouse was placed in the light compartment, and the time
spent in the light compartment was recorded. Oregano
extract was tested at doses of 10, 30 and 60 mg/kg, i.p.;
CLO (16 mg/kg, i.p.; benzodiazepinewith anxiolytic activity)
and VEN (16 mg/kg, i.p.) were used as the reference
compounds.
In vivo microdialysis in the rat hippocampus
In order to assess the ability of oregano extract to increase
extracellular monoamine levels in living brain tissue,
in vivo microdialysis was performed in rats. Previous studies
using potent inhibitors of monoamine transporters, such as
FLU and IMI, have been shown to induce a significant
increase in extracellular serotonin levels following
acute administration in anaesthetised(33,34) and freely-
moving(35–37) rats.
Implantation of microdialysis probes. Rats were
anaesthetised using chloral hydrate (400 mg/kg, i.p.), and a
single microdialysis probe (BASi type MD2200, 2 mm
membrane, 30 000 Dalton cut-off; BASi, Kenilworth, UK)
was implanted in the dorsal hippocampus, using a stereo-
taxic frame, at the following coordinates: rostrocaudal
24·5 mm, mediolateral 22·5 mm and dorsoventral
24·5 mm from the bregma and dural surface(38), and fixed
in position using dental cement. Body temperature was
maintained at 368C using a heating pad and monitored via
a digital rectal thermometer. The microdialysis probe was
perfused with artificial cerebrospinal fluid at 1ml/min, and
perfusate samples were collected every 15 min.
Treatment schedule. Preliminary studies demonstrated
that, following implantation of the microdialysis probe,
the 5-HT level was initially high due to release from plate-
lets activated by blood clotting caused by the surgery.
However, within 150 min of completion of the surgery,
the basal 5-HT level was almost constant. Thus, injections
of the test compound or vehicle were routinely adminis-
tered 150, 210 and 270 min post-surgery (0, 60 and
120 min from the start of the test phase of the experiment),
and perfusate samples were collected until 60 min follow-
ing the final injection. Due to variability in basal 5-HT
release between assays and variability in the efficiency of
the microdialysis probes to detect 5-HT in the extracellular
fluid, data were normalised according to the two values
obtained immediately before the first injection (i.e. 215
and 0 min), and data are expressed as percentage basal
level (means with their standard errors).
Oregano extract was administered at doses of 10, 30 and
60 mg/kg, i.p., and FLU and IMI (both administered at
doses of 3, 10 and 30 mg/kg, i.p.) were used as the reference
compounds. The vehicle used for preparation of oregano
extract was 3 % DMSO/3 % Tween 80 in saline, and the
parallel VEH control group was administered 0·2 % hydroxy-
propylmethylcellulose. The reference compounds were
compared with rats administered saline as vehicle. In initial
studies, all three vehicles had been shown to have the
same effects on 5-HT levels; thus, comparison of oregano
extract (suspended in 3 % DMSO/3 % Tween 80 in saline)
with 0·2 % hydroxypropylmethylcellulose-treated control
rats was deemed justified. On each day of testing, one ore-
gano extract- or reference compound-treated rat was
tested in parallel to one rat administered vehicle.
HPLC analysis of extracellular monoamine levels.
Perfusate samples were assayed immediately for the deter-
mination of extracellular 5-HT and 5-hydroxyindoleacetic
acid (5-HIAA) levels using HPLC with electrochemical
detection. The HPLC mobile phase (0·5 mM-EDTA, 0·1 M-
monochloroacetic acid, pH 3·1, sodium octyl sulphate
(0·15 g/l), 5 % acetonitrile and 0·7 % tetrahydrofuran) was
pumped through the system at 70ml/min, and mono-
amines were separated using a reverse-phase 1 £ 100 mm
octadecyl silane (ODS) 3mm microbore column with
a 5ml injection loop and detected using an Epsilon
A. O. Mechan et al.1154
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electrochemical detector (BASi) with a glassy carbon
electrode set at þ650 mV v. an Ag/AgCl reference elec-
trode. Dialysate peaks were identified by comparing
peak elution times with reference standards and quantified
according to the measurement of peak area using linear
regression analysis. The detection limits for 5-HT and
5-HIAA were defined as the sample amount producing a
peak area twice that of the background noise per unit
time and were both approximately 0·1 fmol/sample.
Following analysis of 5-HT and 5-HIAA levels, the
remaining perfusate samples were stored at 2808C. Sub-
sequently, samples were thawed on ice, and then assayed
for the determination of extracellular NA content. The
HPLC mobile phase (0·5 mM-EDTA, 0·1 M-NaH2PO4, pH
3·1, 1 mM-sodium octyl sulphate and 6 % acetonitrile) was
pumped through the system at 70ml/min, and mono-
amines were separated as described above. The detection
limit for NA was approximately 0·3 fmol/sample.
Analysis of carvacrol levels in plasma and brain tissue
of mice
Sample collection. In order to determine the levels of
CAR, the principal component of oregano extract, in both
plasma and brain tissue, mice were administered oregano
extract (25, 75 or 225 mg/kg, p.o.) 24·5, 18·5, 5·5, 3·5 and
1·5 h before they were killed. Following cervical dislo-
cation and opening of the abdominal and thoracic walls,
blood samples were collected by cardiac puncture using
a sterile syringe and immediately transferred into a poly-
ethylene tube containing heparin. Samples were manually
agitated and stored on ice until centrifugation (48C, 1500 g,
10 min), which was performed within 30 min of sampling.
Plasma was then immediately transferred to polypropylene
tubes and stored at approximately 2708C until analysis.
After blood sampling, each mouse was decapitated
and its brain was removed. Brains were rinsed in cold
physiological saline; hemispheres were dissected on a
refrigerated surface, snap frozen in liquid N2 and stored
at approximately 2708C until analysis.
Chemicals. CAR was obtained from Sigma-Aldrich.
2H-labelled thymol, used as an internal standard for CAR
determination, was obtained from DSM Nutritional Pro-
ducts (Switzerland). Methanol and acetonitrile were of
HPLC grade (Merck, Germany). All other chemicals and
reagents were of analytical grade.
Sample preparation
Plasma. To determine total (aglycone þ conjugated)
CAR concentrations in plasma, 8ml of the internal standard
(2H-labelled thymol, 31·9mg/ml) was added to 25ml of
freshly thawed plasma. Subsequently, digestion with 25ml
b-glucuronidase enzyme (2500 U/ml) in ammonium acetate
buffer (200 mM, pH 5) was performed, by incubating at 378C
for 24 h, before deproteinisation with 100ml acetonitrile.
After shaking horizontally for 10 min, the samples were cen-
trifuged (15 min, 108C), and the resulting supernatant was
subjected to quantitative analysis via liquid chromatography
with tandem MS (LC–MS/MS; see below).
Brain tissue. For quantification of CAR in brain tissue,
approximately 200 mg of brain tissue (one complete hemi-
sphere, without cerebellum) was weighed exactly, and an
equivalent weight of quartz sand (Bu¨chi Labortechnik
AG, Flawil, Switzerland) was added, followed by 1·5 ml
of the internal standard solution (2H-labelled thymol,
335 ng/ml). The mixture was vortexed, mechanically
shaken for 20 min, and then centrifuged (15 min, approxi-
mately 78C). Of the resulting supernatant, 200ml was
then diluted with 400ml of 0·05 % NH4OH solution, and
the mixture was injected on to the LC–MS/MS system.
Apparatus. CAR levels in plasma and brain tissue were
identified and quantified by LC–MS/MS analysis. LC analy-
sis was performed using an Agilent series 1100 system
(Agilent Technologies, Basel, Switzerland) equipped
with a column switching system for online extraction.
The purification column (Waters Xterrae C18, 2·1 mm £
10 mm, 3·5mm) and analytical column (Waters Xterrae
C18, 3·0 mm £ 50 mm, 2·5mm) were used at room tempera-
ture. Gradient elution for both columns was a mixture of
0·05 % NH4OH solution and acetonitrile. The volume of
injection was 50ml, and the autosampler was set to 108C.
A triple quadrupole mass spectrometer (API Q TRAP4000;
Applied Biosystems, Rotkreuz, Switzerland) equipped
with a Heated Nebuliser (APCI) source in negative mode
was used for the detection of compounds of interest. The
criteria for identification and quantification were the
retention time and multiple reaction monitoring transition,
149! 134 for CAR and 151! 136 for 2H-labelled thymol
(internal standard).
Identification, calibration and quantification of
carvacrol. The identification of CAR was carried out by
comparing retention times with an authentic reference
standard. Moreover, specific identifications were obtained
by using multiple reaction monitoring signals of the
LC–MS/MS system. Data acquisition of extracted ion
chromatograms, integration and quantification was per-
formed using Analystw Software from Applied Biosystems,
Inc. (Foster City, CA, USA). Quantification was performed
by applying an external standard calibration curve cover-
ing the range of unknown samples. Additionally, quality
of the analytical data was ensured by using quality-control
samples. Calibration- and quality-control samples were
analysed in the same manner as the unknown samples.
The lower limit of quantification was set to 0·020mg/ml
for total CAR in the plasma, and to 0·025mg/g for CAR in
the brain.
Statistics
All data are shown as means with their standard errors, and
significance levels of comparisons between means are all
two-sided. The in vitro data are presented as the percen-
tage of inhibition values, which were calculated relative
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to the fully inhibited controls from the same plate. Analysis
of screening data was performed using MDLw Assay
Explorerw 2.2 (Symyx Software, San Ramon, CA, USA),
and curve fitting was performed using Origin 7 (OriginLab
Corporation, Northampton, MA, USA).
Statistical analyses of all behavioural data and CAR data
analyses were performed using SPSS (SPSS 17.0.1 ML R1;
SPSS, Inc., Chicago, IL, USA). Inter-group comparisons
were made using one-way ANOVA and, where appropriate,
post hoc tests enabled pairwise comparisons; where
homogeneity of variance occurred, a least significant
difference post hoc test was used, where variances were
non-homogeneous, Tamhane’s T2 test was used.
In vivo microdialysis data were analysed using GraphPad
Prism (GraphPad Prism 3.0; GraphPad Software, Inc.,
La Jolla, CA, USA). Statistical comparison of the level of
5-HT or NA in the perfusate following administration of
the test compound or vehicle was made by two-way
ANOVA (test factors being treatment and time), followed
by post hoc comparisons at individual time points using
the Bonferroni t test.
Results
In vitro inhibition of human serotonin, noradrenaline and
dopamine transporters, and monoamine oxidase-A and -B
enzymes
High-throughput screening of a library containing
more than 32 000 fractions, derived from 2400 pure
phytochemicals and extracts of more than 500 edible
plants, was performed. The primary screen comprised a
non-radioactive, hSERT functional assay using hSERT-
expressing HEK cells and identified a specific, supercritical
fluid CO2 oregano extract as having strong (61 %) inhibi-
tory activity. This result was confirmed in a subsequent
assay using uptake of radiolabelled serotonin, where the
oregano extract was shown to inhibit hSERT function in
a reproducible and dose-dependent manner, with an IC50
of 3·2 (SEM 1·4)mg/ml (n 3). Further profiling of the same
extract against other relevant targets revealed a dose-
dependent inhibition of hNAT, hDAT and MAO-A and
MAO-B, although the inhibition of MAO-B was consider-
ably weaker than that of MAO-A. The inhibition of the
MAO enzymes was fully reversible (data not shown).
Representative dose–response curves for the effects of ore-
gano extract on hSERT, hNAT, hDAT, MAO-A and MAO-B
are shown in Fig. 1.
Oregano extract and carvacrol/thymoquinone spike assay
When increasing concentrations (1, 3·16, 10, 31·6 and
100mM) of TQ or CAR were added to the IC50 concen-
tration (40mg/ml) of oregano extract (containing
0·244mM-TQ þ 1·6mM-CAR), percentage inhibition of
hSERT was consistently increased above that of TQ or
CAR alone (Table 1). These data thus indicate the import-
ance of TQ and CAR in the serotonin reuptake inhibitory
activity of oregano extract.
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Fig. 1. Dose-dependent inhibition of (a) human serotonin, (b) human noradrenaline, (c) human dopamine transporters, (d) monoamine oxidase-A (MAO-A) and (e)
monoamine oxidase-B (MAO-B) by oregano extract. Concentration refers to mg/ml in the case of oregano extract (–X–; half maximal inhibitory concentration
(IC50) ¼ (a) 1·7, (b) 9·5, (c) 6·7, (d) 2·6 and (e) 10·5mg/ml) and mM for the reference compounds (–K–) ((a) fluoxetine (IC50 ¼ 4·8 nM), (b) desipramine
(IC50 ¼ 2·1 nM), (c) nomifensine (IC50 ¼ 10·6 nM), (d) clorgyline (IC50 ¼ 5·5 nM) and (e) Ro16-6491 (IC50 ¼ 216 nM), respectively). Values are means, with standard
errors represented by vertical bars (three wells). In each case, raw data are shown together with curves of best fit, enabling the calculation of IC50 values.
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Effects of oregano extract in mouse behavioural tests
Forced swim test. The activity of oregano extract in the
forced swim test was assessed following both acute and
sub-chronic administration. Acute treatment (oregano
extract (OREG); 30 and 60 mg/kg, i.p., 30 min before beha-
vioural testing) resulted in a significant reduction in the
duration of immobility, compared with VEH control mice,
by 17 and 24 %, respectively (significant effect of group:
F(5,89) ¼ 26·814, P,0·001; VEH v. OREG-30: P¼0·032,
VEH v. OREG-60: P¼0·003; Fig. 2(a)). The reduction in
immobility was unlikely to be due to overall changes in
locomotor activity, as neither stimulatory nor inhibitory
effects of the extract were observed in a previous study
comprising assessment of spontaneous locomotor activity
in automated activity meters (Imetronic, Pessac, France;
AO Mechan, unpublished results). The reference com-
pounds, IMI (32 mg/kg) and VEN (16 mg/kg), significantly
reduced the duration of immobility by 70 and 51 %,
respectively (P,0·001). Sub-chronic, oral administration
of oregano extract (75, 150 and 300 mg/kg, p.o., 24, 5
and 1 h before testing) was effective in reducing the
duration of immobility, compared with VEH mice, by 41,
32 and 21 %, respectively. This activity reached statistical
significance at the low and intermediate doses and
was comparable with the effects of IMI (32 mg/kg) (signifi-
cant effect of group: F(4,49) ¼ 3·958, P¼0·008; VEH
v. OREG-75: P¼0·005, VEH v. OREG-150: P¼0·024, VEH
v. IMI: P¼0·001; Fig. 2(b)).
Marble-burying test. Anxiolytic effects of oregano
extract (10, 30 and 60 mg/kg, i.p., administered 30 min
before testing) were indicated by a reduction in the
number of marbles buried (40, 73 and 67 %, respectively)
compared with control mice (significant effect of group:
F(5,89) ¼ 14·858, P,0·001; VEH v. OREG-30 and VEH
v. OREG-60: P¼0·001; Fig. 3). The observed effects were
in agreement with the effects of the reference compounds,
VEN (16 mg/kg, i.p., 230 min) and FLU (32 mg/kg,
i.p., 230 min), which significantly reduced the number of
marbles buried by 98 and 93 %, respectively (P,0·001).
Light–dark box test. To further explore the anxiolytic
potential of oregano extract, mice were subjected to the
light–dark box test. Oregano extract (10 and 60 mg/kg,
i.p., 30 min before testing) increased the time spent in
the light compartment, compared with control mice, by
28 and 35 %, respectively, while the reference compound,
CLO (16 mg/kg, i.p., 230 min), increased the time spent
by 114 % (significant effect of group: F(5,89) ¼ 12·723,
P,0·001; VEH v. OREG-60: P¼0·046, VEH v. CLO:
P,0·001; Fig. 4).
In vivo efficacy of oregano extract as a serotonin
transporter inhibitor
In vivo microdialysis studies in rats revealed that extracellu-
lar 5-HT levels in the hippocampus were slightly, but
consistently, higher than in the VEH animals after each
dose of oregano extract. Furthermore, additional transient
increases after 30 and 60 mg/kg were observed (Fig. 5(a)).
Analysis of 5-HT levels by two-way ANOVA over the entire
period of investigation revealed a significant effect of
treatment (F(1,133) ¼ 11·0, P,0·01) but no significant
interaction effect of treatment £ time (F(13,133) ¼ 0·54,
P.0·05). Timed comparison of 5-HT levels indicated no
significant differences between oregano extract and vehicle
at any specific time point, thus indicating continuously
higher extracellular 5-HT levels in the brains of oregano
extract-treated rats. Comparison of 5-HIAA levels showed
no significant difference between oregano extract and
vehicle (data not shown). The basal levels of 5-HT (5·77
(SEM 0·91) fmol/sample) and 5-HIAA (1102 (SEM 53) fmol/
sample) in the oregano extract assays were not significantly
different from the basal levels in the vehicle assays.
The reference compounds, both FLU and IMI, induced
significant increases in extracellular 5-HT levels, as expected
(Fig. 5(b)). FLU treatment resulted in an overall significant
effect of treatment (F(1,129) ¼ 192·5, P,0·001) and a signifi-
cant interaction of treatment £ time (F(13,129) ¼ 9·942,
P,0·001), and significantly higher levels of extracellular
Table 1. Thymoquinone (TQ) or carvacrol (CAR) (1–100mM) was added to oregano extract (OREG; half maximal inhibitory concentration 40mg/ml),
which itself contained low levels of the two compounds (0·1 % (0·244mM) and 0·6 % (1·6mM), respectively)†
(Mean values with their standard errors, n 4)
TQ or CAR
concentration (mM)
Percentage inhibition of hSERT
TQ
OREG
(40mg/ml) þ TQ
Average increase
in inhibition (%)
CAR
OREG
(40mg/ml) þ CAR
Average increase
in inhibition (%)Mean SEM Mean SEM Mean SEM Mean SEM
1 30·41 8·23 58·09 2·96 þ27·68* 12·70 2·04 51·68 5·14 þ38·98***
3·16 27·54 1·17 58·19 0·91 þ30·65*** 10·54 10·21 52·06 2·49 þ41·52**
10 60·76 2·59 78·71 3·22 þ17·95** 1·40 4·02 53·33 2·21 þ51·93***
31·6 52·95 4·30 80·77 1·63 þ27·82*** 23·69 3·98 71·26 1·51 þ47·57***
100 50·58 4·53 86·26 1·59 þ35·68*** 24·57 2·23 78·74 0·70 þ54·17***
hSERT, human serotonin transporter.
Percentage inhibition values were significantly different (TQ alone v. OREG þ TQ, CAR alone v. OREG þ CAR): *P,0·05, **P,0·01, ***P,0·001.
† Percentage inhibition of radiolabelled serotonin uptake for TQ and CAR alone and for OREG þ TQ and OREG þ CAR. The single compounds were marginally active, while
their addition to oregano extract induced a consistent upward shift in the percentage inhibition curve compared with oregano extract alone.
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5-HT were induced following the second dose of FLU
(P,0·05 at all time points after 60 min). In IMI-treated rats,
a significant overall treatment effect was observed
(F(1,128) ¼ 37·17, P,0·001), but no interaction effect of
treatment £ time, while post hoc analysis revealed a signifi-
cant difference between IMI- (30 mg/kg) and VEH rats at
150 min (P,0·05). Comparison of 5-HIAA levels showed
no significant effect of either FLU or IMI, compared with
vehicle, at any time point (data not shown).
Following each administration of oregano extract (10, 30
and 60 mg/kg, i.p.), the NA level increased and then
returned to, or below, baseline before administration of
the subsequent dose (Fig. 5(c)). However, comparison
of NA levels by two-way ANOVA over the full period of
investigation revealed no significant effect of treatment
(F(1,133) ¼ 11·0, P,0·60) or interaction effect of
treatment £ time (F(13,133) ¼ 1·04, P.0·05). Timed com-
parison of NA levels indicated no significant differences
between oregano extract and vehicle at any individual time
point. The basal levels of NA (20·7 (SEM 4·1) fmol/sample)
in the oregano extract assays were not significantly
different from the basal levels in the vehicle assays.
The positive control compound, FLU, had no effect
on NA levels (data not shown). NA levels were unaltered
by the lowest dose of IMI, while 10 mg/kg induced
a slight, but consistent, increase and, after administration
of 30 mg/kg, NA levels were significantly greater than
observed in saline-treated control animals (Fig. 5(d)).
Thus, a significant overall effect of treatment
(F(1,128) ¼ 90·3, P,0·001) and a significant interaction
effect of treatment £ time (F(13,128) ¼ 5·27, P,0·001)
were observed, in addition to significant increases at
all time points after 120 min (P,0·05).
Analysis of carvacrol levels in mouse plasma and brain
We have established an analytical method to quantify
CAR, the principal component of oregano extract, in
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Fig. 2. Forced swim test. (a) Mice (n 15) were administered the test com-
pound or vehicle, intraperitoneally, 30 min before the start of the test: vehicle
(VEH; 3 % dimethyl sulphoxide/3 % Tween 80 in saline), venlafaxine (VEN;
16 mg/kg), imipramine (IMI; 32 mg/kg) and oregano extract (OREG; 10, 30 or
60 mg/kg). (b) Mice (n 10) were administered the test compound or vehicle,
per os, 24, 5 and 1 h before the start of the test: VEH (maize oil), IMI
(32 mg/kg) and OREG (75, 150 or 300 mg/kg). Duration of immobility, calcu-
lated as a percentage of total test time during the last 4 min of a 6 min test, is
shown as means, with standard errors represented by vertical bars. Mean
values were significantly different compared with the VEH control group:
*P,0·05, **P,0·01, ***P,0·001. OREG-30 and OREG-60 significantly
reduced immobility behaviour, in agreement with the effects of both reference
compounds. OREG-75 and OREG-150 significantly reduced immobility beha-
viour, in agreement with the effects of IMI.
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Fig. 3. Marble-burying test. Mice were administered the test compound or
vehicle, intraperitoneally, 30 min before the start of the test: vehicle (VEH;
3 % dimethyl sulphoxide/3 % Tween 80 in saline), venlafaxine (VEN;
16 mg/kg), fluoxetine (FLU; 32 mg/kg) and oregano extract (OREG; 10, 30 or
60 mg/kg). The number of marbles buried during a 30 min test, calculated as
a percentage of the total number of marbles present, is shown as means,
with their standard errors represented by vertical bars (n 15). Mean values
were significantly different compared with the vehicle control group:
**P,0·01, ***P,0·001. OREG-30 and OREG-60 significantly reduced
marble-burying behaviour, in agreement with the effects of both reference
compounds.
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mouse plasma and brain tissue following oral adminis-
tration (25, 75 and 225 mg/kg, p.o., 24·5, 18·5, 5·5, 3·5
and 1·5 h before tissue collection). Clear, dose-dependent
CAR levels were observed in the plasma (significant
effect of treatment: F(3,39) ¼ 185·146, P,0·001; post hoc
comparisons of each treatment group with VEH:
P,0·001; Fig. 6(a)). In brain tissue, CAR levels were
below the limit of quantification (,0·025mg/g) in all ten
mice after administration of 25 mg/kg, and in eight out of
ten mice after administration of 75 mg/kg. Nevertheless,
75 and 225 mg/kg resulted in CAR levels of 0·08 (SEM
0·03)mg/g and 0·19 (SEM 0·09)mg/g, respectively (signifi-
cant effect of treatment: F(3,39) ¼ 3·93, P¼0·016; VEH v.
OREG-225: P¼0·007; Fig. 6(b)).
Discussion
The results of the present study show that a supercritical
fluid CO2 oregano extract, comprising a specified range
of active constituents, acts as a moderate, natural, seroto-
nin, NA and dopamine reuptake inhibitor, in addition to
inhibiting monoamine catabolism in vitro. Subsequently,
oregano extract was demonstrated to elevate brain extra-
cellular serotonin levels in rats and to induce behavioural
changes in mice characteristic of those generated by
antidepressant- and anxiolytic-like compounds.
The monoamine neurotransmitters are involved in the
mediation of a wide range of physiological and beha-
vioural functions, including the sleep–wake cycle, appe-
tite, mood, aggression(8), locomotor activity, cognition,
emotion(9), attention, anxiety, arousal, learning and
memory(6). Therefore, dysregulation of one or more of
the monoaminergic neurotransmitter pathways could
result in alterations in mood, appetite, sleep and cognitive
function. In clinical terms, treatment of mood disorders,
including depression, is preferentially achieved through
inhibition of one or more of the monoaminergic neuro-
transmitter reuptake transporters. In addition, extensive
research during the past decade has led to the hypothesis
that antidepressants with triple reuptake inhibitory activity
may have a more rapid onset of effect and better efficacy
over currently prescribed reuptake inhibitors of serotonin
and/or NA, in part due to the addition of the dopamine
component(39–42).
The ultimate aim of the present study was not to identify
a clinical antidepressant, but a plant-derived pure com-
pound or plant extract with the potential for the enhance-
ment of mood or mental well-being. To this end, we
focused on increased synaptic activity of serotonin, NA
and dopamine through inhibition of their reuptake. The
results of the in vitro binding assays clearly showed that
oregano extract had a triple reuptake inhibitor profile,
exemplified by dose-dependent inhibition of the uptake
of radioactively labelled serotonin, NA and dopamine. In
addition, oregano extract dose dependently and reversibly
inhibited the enzymatic activity of MAO-A. The reversibility
of the inhibition is important for the prevention of side
effects, such as hepatotoxicity, orthostatic hypotension
and hypertensive crisis, as associated with the earlier
MAO inhibitors(25). The complementary effects of inhibit-
ing both reuptake of the monoamine neurotransmitters
and their enzymatic degradation provide the possibility
of greater synaptic monoamine levels than would be the
case for a compound which selectively inhibits either the
uptake transporters or MAO, particularly following chronic
dosing. It should be noted here that the IC50 values for
uptake inhibition and enzymatic activity were approxi-
mately 1000-fold lower than the IC50 values of the respect-
ive pharmacological reference compounds used in the
present study. We postulate that such activity would be
associated with the beneficial, mood-enhancing effects of
triple reuptake inhibitors and MAO inhibitors while mini-
mising the potential for side effects.
Microdialysis studies in rats demonstrated that oregano
extract induced a small, but significant, increase in extra-
cellular serotonin levels in the brain. Although consider-
ably smaller than the effects of the tested reference
compounds, FLU and IMI, this nevertheless indicates effec-
tive brain penetrance and neurochemical activity of ore-
gano extract to increase synaptic levels of serotonin,
most likely through inhibition of the serotonin transporter.
In order to assess the in vivo effects of oregano extract
on behaviour, the optimal models were determined to be
those where compounds with known monoamine
reuptake inhibitory activity have proven efficacy(43–47).
Consequently, mice were subjected to the forced swim
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Fig. 4. Light–dark box test. Mice were administered the test compound or
vehicle, intraperitoneally, 30 min before the start of the test: vehicle (VEH;
3 % dimethyl sulphoxide/3 % Tween 80 in saline), venlafaxine (VEN;
16 mg/kg), clobazam (CLO; 16 mg/kg) and oregano extract (OREG; 10, 30 or
60 mg/kg). Time spent in the light compartment during a 3 min test is shown
as means, with their standard errors represented by vertical bars (n 15).
Mean values were significantly different compared with the vehicle control
group: *P,0·05, ***P,0·001. OREG-60 induced significant increases in time
spent in the light compartment, in agreement with the effects of CLO.
Mood-enhancing potential of oregano extract 1159
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114510004940
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:37:30, subject to the Cambridge Core terms of use, available at
test(43,44), marble-burying test(45) and light–dark box
test(46,47). Acute administration of oregano extract resulted
in a dose-dependent reduction of immobility behaviour in
the forced swim test, in agreement with effects of the refer-
ence compounds, IMI and VEN, both of which have dual
serotonin/NA reuptake inhibitory activity and have been
proven efficacious in this behavioural paradigm(48,49). By
analogy, the observed effect of oregano extract was there-
fore suggestive of mood-enhancing activity in human
subjects. Furthermore, acute treatment with oregano
extract resulted in anxiolytic-like effects in both the
marble-burying and light–dark box tests. Oregano extract
significantly reduced the number of marbles buried in
the marble-burying test, in concordance with the effects
of FLU (serotonin reuptake inhibitor) and VEN, both
within the present study and as reported in the litera-
ture(50–52). Acute administration of oregano extract
resulted in significant increases in the time spent in the
light compartment of the light–dark box, which is
suggested to be indicative of anxiolytic activity(53). Our
data are supported by a recent study describing the anxio-
lytic-like effect of CAR, the major constituent of oregano
extract, in mice in the elevated plus-maze test(54).
Subsequently, oregano extract was orally administered
to mice in a sub-chronic dosing regimen before testing in
the forced swim test. Immobility behaviour was reduced
by all three doses tested, the lowest dose having the great-
est effect. The fact that the lowest dose of oregano extract
was the most active, and that significant effects were not
observed above a dose of 150 mg/kg, indicates that its
behavioural activity lies within a particular dose range
and may be saturable in vivo. Most importantly, oregano
extract, following both acute, i.p. administration and
sub-chronic, p.o. administration, demonstrated statistically
significant effects in a widely used rodent model in
which compounds with monoamine reuptake inhibitory
activity, shown to elevate depressed mood in human sub-
jects, have proven efficacy(43,44). Moreover, the observed
effects are in agreement with a recent study demonstrating
a significant reduction in immobility behaviour in the
forced swim test following administration of another com-
monly used plant, Rosmarinus officinalis. The reported
effects were shown to be due to interactions with monoa-
minergic neurotransmission and were suggested to be
dependent upon its interaction with several receptor
subtypes (5-HT1A, 5-HT2A, 5-HT3, a1, D1 and D2)
(55).
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Fig. 5. In vivo microdialysis in the rat hippocampus. Rats were administered vehicle (VEH, –W–), oregano extract (OREG, –X–; 10, 30 and 60 mg/kg), fluoxetine
(FLU, –D–; 3, 10 and 30 mg/kg) or imipramine (IMI, –O–; 3, 10 and 30 mg/kg), intraperitoneally, at 0, 60 and 120 min. Extracellular monoamine levels ((a and b)
serotonin (5-hydroxytryptamine; 5-HT), (c and d) noradrenaline (NA)) are shown as means, with their standard errors represented by vertical bars (n 4–6), and
are expressed as percentage basal values. Mean values were significantly different compared with the respective vehicle control group (*P,0·05; Bonferroni post
hoc test). OREG induced an overall increase in the extracellular levels of 5-HT (a) while having no statistically significant effect on NA levels (c). Both FLU and
IMI significantly increased 5-HT levels (b), while only IMI increased NA levels (d).
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In order to investigate which of the constituents of
oregano extract may be responsible for the observed
inhibition of serotonin reuptake, an additional hSERT
inhibition assay was performed. The addition of TQ or
CAR to the IC50 concentration of oregano extract (containing
0·244mM-TQ and 1·6mM-CAR) significantly increased
the percentage inhibition of hSERT, suggesting that
the presence of both compounds contributes to the bio-
logical activity profile of our oregano extract. In addition,
dose-dependent plasma CAR levels were observed in mice
administered multiple doses of oregano extract, and the
two higher doses resulted in measurable levels of CAR
within brain tissue, thus further indicating that an active com-
ponent of oregano extract crosses the blood–brain barrier.
We have shown here, through cellular uptake inhibition
assays, in vivo microdialysis and rodent behavioural tests,
that oregano extract acts as a triple reuptake inhibitor
in vitro, moderately increases brain extracellular serotonin
levels and induces positive behavioural effects in animal
models, which are associated with antidepressant- and
anxiolytic-like activity when compounds with a similar
profile are administered to human subjects. To the best
of our knowledge, oregano extract is the first nutritional
ingredient exhibiting all of the aforementioned properties.
In addition, both the in vitro and in vivo data indicate that
our oregano extract demonstrates moderate efficacy, in
comparison with pharmaceutical antidepressant or anxio-
lytic compounds, as would be expected for a dietary
constituent. We suggest that, in agreement with published
studies on M. officinalis (11), S. lavandulaefolia (12,13) and
S. officinalis (14), where attention(11), mood(12) and
memory(12–14) were improved with nutritional supple-
mentation, oregano extract may comprise a viable strategy
to maintain a healthy mood status and enhance mental
well-being in humans and propose the initiation of
appropriate investigations.
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